Pharmacovigilance Agreements (PVAs) are agreements between two companies based on their Commercial Agreements that require an exchange of safety information between the two companies. PVAs are not stand alone agreements but dependent on the relationships established between two companies regarding at least one medicinal and/or developmental product. The existence of strong PVAs is necessary to support the safety of the product and patient safety globally. PVAs may also be referred to as Safety Data Exchange Agreements by some pharmaceutical companies.
You may also be interested in:
Case Study
PRA Leads Novel Multiple Myeloma Drug Development
PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract…
Newsletter
PV Nugget #6 Literature Surveillance
Literature is regarded as a significant source of information in the monitoring of a medicinal product, its safety profile, and benefit-risk balance.…
Blog
Ask the Experts: What Role Does Patient Safety Play in Our Industry?
When it comes to safety, PRA puts its patients and its people first. Clinical trials are meticulous, with many moving pieces and crucial steps. It’s…